

By: Springer

S.B. No. 403

A BILL TO BE ENTITLED

AN ACT

relating to a study on the side effects, adverse reactions, including death, and the effectiveness of vaccines against the SARS-CoV-2 virus (COVID-19) or its variants.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:

SECTION 1. (a) In this section:

1) "Commission" means the Health and Human Services Commission.

2) "Executive commissioner" means the executive commissioner of the Health and Human Services Commission.

3) "Department" means the Department of State Health Services.

4) "COVID-19" means the SARS-CoV-2 virus and any of its variants.

5) "Vaccine" means a substance used to stimulate immunity to a particular infectious disease or pathogen, typically prepared from an inactivated or weakened form of the causative agent or from its constituents or products.

(b) The Commission in collaboration with the Department shall conduct a study to assess the full and complete adverse reactions, including death, and effectiveness of each type of vaccine used in Texas to defend the human body against "COVID-19. The Report must include:

1) The immediate short-term side effects and adverse

1 reactions recipients experienced from taking the various COVID-19
2 vaccines used in Texas; including but not limited to include:

- 3 i. Pain, swelling, or redness where the shot was given
- 4 ii. Mild fever
- 5 iii. Chills
- 6 iv. Feeling tired
- 7 v. Headache
- 8 vi. Muscle and joint aches

9 2) The immediate serious side effects and adverse reactions
10 recipients experienced from taking the various COVID-19 vaccines
11 used in Texas; including but not limited to include:

- 12 i. difficulty breathing;
- 13 ii. swelling of the face and throat;
- 14 iii. accelerated heartbeat;
- 15 iv. a body rash;
- 16 v. dizziness; and
- 17 vi. weakness

18 3) Any long-term side effects and adverse reactions
19 recipients have experienced from taking the various COVID-19
20 vaccines used in Texas; including but not limited to include:

- 21 i. paralysis;
- 22 ii. Myocarditis;
- 23 iii. clotting disorders;
- 24 iv. Thrombosis with Thrombocytopenia Syndrome (TTS);
- 25 v. Guillain-Barré syndrome (GBS);
- 26 vi. difficulty thinking or "brain fog,"
- 27 vii. chronic pain;

- viii. tiredness and fatigue;
- ix. loss of taste;
- x. depression;
- xi. anxiety; and
- xii. death.

4) Any misrepresentations about the effectiveness or dangers of taking of the vaccine by its manufacturers or any governmental agency; and,

5) Any concealment of information about the effectiveness or dangers of taking of the vaccine by its manufacturers or any governmental agency.

(c) The Commission and the Department shall gather information for the report from:

1) information collected by the Commission and the Department, including information from the department's vital statistics unit and the state Medicaid program;

2) hospitals, treatment centers, available surveys; and

3) and other relevant sources.

SECTION 2. (a) Not later than January 1, 2024, the Commission and Department shall prepare and submit to the Governor, Lieutenant Governor, the Speaker of the House of Representatives, and the Chairpersons of the relevant Texas legislative committees with jurisdiction over the Commission and the Department, a copy of the report, summary of any findings, and any recommendations for legislative or executive action to reduce the prevalence of COVID-19 Vaccine side effects. The department may post the report on the department's Internet website.

1 (b) The Commission and Department may accept gifts, grants,
2 and donations from any source to fund expenses
3 incurred by the Commission and the Department in
4 preparing the report.

5 SECTION 3. This Act expires September 1, 2025.

6 SECTION 4. This Act takes effect immediately if it receives a vote
7 of two-thirds of all the members elected to each house, as provided
8 by Section 39, Article III, Texas Constitution. If this Act does
9 not receive the vote necessary for immediate effect, this Act takes
10 effect September 1, 2023.